Aquestive(US:AQST) Prnewswire·2026-03-12 13:19Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. related to a federal securities class action, with a deadline for investors to seek lead plaintiff status by May 4, 2026 [1] Company Overview - Aquestive Therapeutics, Inc. (NASDAQ: AQST) is facing allegations of violating federal securities laws by making false or misleading statements regarding its New Drug Application (NDA) for Anaphylm [1] - The company is accused of concealing the significance of human factors in the use of its sublingual film, including aspects like packaging, administration, and labeling [1] Stock Performance - Following the announcement of deficiencies identified by the FDA in the NDA for Anaphylm on January 9, 2026, Aquestive's stock price dropped by $2.30 per share, representing a decline of 37.04%, closing at $3.91 per share [1] Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members and will oversee the litigation [1] - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [1]